0001600620-24-000087.txt : 20240614 0001600620-24-000087.hdr.sgml : 20240614 20240614172528 ACCESSION NUMBER: 0001600620-24-000087 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240614 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981231763 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 241046086 BUSINESS ADDRESS: STREET 1: #140, 14315 - 118 AVENUE CITY: EDMONTON STATE: A0 ZIP: T5L 4S6 BUSINESS PHONE: 250-744-2487 MAIL ADDRESS: STREET 1: #140, 14315 - 118 AVENUE CITY: EDMONTON STATE: A0 ZIP: T5L 4S6 8-K 1 auph-20240614.htm 8-K auph-20240614
0001600620FALSE00016006202024-06-142024-06-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2024
Aurinia Pharmaceuticals Inc.
(Exact name of registrant as specified in its charter)
Alberta, Canada 001-36421 98-1231763
(State or Other Jurisdiction of Incorporation)
 
(Commission File No.)
 
(IRS Employer Identification No.)

#140, 14315 – 118 Avenue
Edmonton, Alberta
T5L 4S6
(250) 744-2487
(Address and telephone number of registrant's principal executive offices)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class 
Trading Symbol(s)
 
Name of Each Exchange on which Registered
Common Shares, without par value AUPH The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐


Item 5.07
Submission of Matters to a Vote of Security Holders.

(a)The Company held its annual general meeting of shareholders (the "2024 Meeting") virtually on June 14, 2024.

(b)The following proposals were voted upon at the 2024 Meeting and the final voting results with respect to each such proposal are set forth below:

Proposal 1: At the 2024 Meeting, shareholders voted on the election of Dr. Daniel Billen, Mr. Peter Greenleaf, Dr. David R.W. Jayne, Mr. R. Hector MacKay-Dunn, Ms. Jill Leversage, Dr. Brinda Balakrishnan, Dr. Karen Smith, Mr. Jeffrey A. Bailey and Dr. Robert T. Foster to serve as members of the Company's board of directors until the annual general meeting of shareholders to be held in 2025.

NomineeForWithheldBroker Non-Votes
Dr. Daniel Billen33,343,24543,247,44119,865,665
Mr. Peter Greenleaf36,942,21439,681,65719,832,480
Dr. David R.W. Jayne47,961,38228,672,48819,822,481
Mr. R. Hector MacKay-Dunn35,001,81941,588,86619,865,666
Ms. Jill Leversage48,882,66827,741,20219,832,481
Dr. Brinda Balakrishnan36,406,54440,184,13919,865,668
Dr. Karen Smith38,979,54437,644,48519,832,322
Mr. Jeffrey A. Bailey
38,651,71137,972,31919,832,321
Dr. Robert T. Foster39,405,04637,218,98419,832,321

Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who received less than majority support are Peter Greenleaf, Director, President and CEO; Daniel G. Billen, Ph.D., Director, Chair of the Board, Chair of the Compensation Committee, and Member of the Audit Committee; R. Hector MacKay-Dunn, J.D., K.C., Director, Chair of the Governance & Nomination Committee and Member of the Compensation Committee; and Brinda Balakrishnan, M.D., Ph.D., Director, Member of the Compensation Committee.

As required by the Company’s Majority Voting Policy, these directors have submitted their conditional resignations as directors of the Company for consideration by the Board. Pursuant to the Majority Voting Policy, the Board will consider these conditional resignations and communicate their decision and resulting actions within the 90-day period specified in the Majority Voting Policy.

Proposal 2: Based upon the following votes, the shareholders approved the appointment of PricewaterhouseCoopers LLP, Chartered Professional Accountants, as the Company's independent registered public accounting firm until the annual general meeting of shareholders to be held in 2025 or until a successor is appointed.

ForAgainstAbstainBroker Non-Votes
85,574,5678,080,6422,801,1411



Proposal 3: Based upon the following votes, the shareholders did not approve on a non-binding advisory basis, a "say on pay" resolution regarding the Company's executive compensation.

ForAgainstAbstainBroker Non-Votes
30,780,03345,321,684522,31419,832,320

Proposal 4: Based upon the following votes, the shareholders did not approve the Company's Amendment to the Equity Incentive Plan.

ForAgainstAbstainBroker Non-Votes
35,700,70240,481,025442,30119,832,323

Item 9.01Financial Statements and Exhibits
(d) Exhibits.
Exhibit No.Description
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 14, 2024

AURINIA PHARMACEUTICALS INC.
By:/s/ Stephen P. Robertson
Name:Stephen P. Robertson
Title:
Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer



 EX-101.SCH 2 auph-20240614.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 auph-20240614_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 4 auph-20240614_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover Page
Jun. 14, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 14, 2024
Entity Registrant Name Aurinia Pharmaceuticals Inc.
Entity Incorporation, State or Country Code A0
Entity File Number 001-36421
Entity Tax Identification Number 98-1231763
Entity Address, Address Line One #140, 14315 – 118 Avenue
Entity Address, City or Town Edmonton
Entity Address, State or Province AB
Entity Address, Postal Zip Code T5L 4S6
City Area Code 250
Local Phone Number 744-2487
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, without par value
Trading Symbol AUPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001600620
Amendment Flag false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.auriniapharma.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports auph-20240614.htm auph-20240614.xsd auph-20240614_lab.xml auph-20240614_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "auph-20240614.htm": { "nsprefix": "auph", "nsuri": "http://www.auriniapharma.com/20240614", "dts": { "inline": { "local": [ "auph-20240614.htm" ] }, "schema": { "local": [ "auph-20240614.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "auph-20240614_lab.xml" ] }, "presentationLink": { "local": [ "auph-20240614_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.auriniapharma.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240614.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "auph-20240614.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.auriniapharma.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001600620-24-000087-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001600620-24-000087-xbrl.zip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end XML 16 auph-20240614_htm.xml IDEA: XBRL DOCUMENT 0001600620 2024-06-14 2024-06-14 0001600620 false 8-K 2024-06-14 Aurinia Pharmaceuticals Inc. A0 001-36421 98-1231763 #140, 14315 – 118 Avenue Edmonton AB T5L 4S6 250 744-2487 false false false false Common Shares, without par value AUPH NASDAQ false